OKYO Pharma Limited

OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.